
Bajaj Healthcare's Shares Soar on Drug Approval News
Bajaj Healthcare's shares surged nearly 10% to a new 52-week high of Rs 740 on March 19, following the approval for Phase III clinical trials of its anti-seizure drug, Cenobamate. The stock later adjusted to Rs 731, still up 8% from the previous close. The Central Drugs Standard Control Organisation (CDSCO) has recommended the trials for various strengths of Cenobamate, which aims to treat partial onset seizures in adults by controlling excessive neuronal activity. This phase is crucial before seeking final regulatory approval for the drug's commercial launch. Bajaj Healthcare is dedicated to providing effective epilepsy treatments in India.